The agreement announced Monday calls for Sanofi to fill vials and finish packaging for Moderna’s vaccine at Sanofi’s plant in Ridgefield.
Sanofi is the only pharmaceutical company with agreements to help manufacture three different COVID-19 vaccines. In addition to the Moderna vaccine, Sanofi has also committed to help make more than 125 million doses of the Pfizer-BioNTech vaccine and about 12 million doses a month of J&J’s vaccine.
The Pfizer-BioNTech vaccine is being manufactured at a Sanofi plant in Germany this summer and the J&J vaccine will be produced at Sanofi plant in France.
“Since the beginning of the pandemic, we have been mobilizing on multiple fronts and we showed solidarity across the industry,” Sandofi CEO Paul Hudson said.
“We are one of the few pharmaceutical companies to leverage many industrial partnerships to improve equitable global supply and access to COVID-19 vaccines, while in parallel, also continuing to develop our two COVID-19 vaccine programs,” Hudson said.
Sanofi is developing two potential Covid-19 vaccine candidates. One is in collaboration with GlaxoSmithKline, and another is with Translate Bio Inc.
The vaccine being developed With GlaxoSmithKline uses the same recombinant protein-based manufacturing technology as one of Sanofi’s seasonal influenza vaccines. A Phase 2 study of this vaccine with 720 enrolled participants was completed on March 8 and results are expected in Q2 of 2021.
Sanofi is also developing a messenger RNA vaccine in partnership with Translate Bio. In March, Sanofi and Translate Bio initiated a Phase 1/2 clinical trial of their mRNA COVID-19 vaccine candidate.